Why Global X Aging Population ETF (AGNG) Is Up +11% in the Last 30 Days
Key Takeaways
- The Global X Aging Population ETF (AGNG) rose roughly 11% over the trailing 30 days, climbing from about $36.20 to $40.28 per share.
- AGNG is a thematic healthcare fund, allocating roughly 91% of assets to healthcare and about 9% to senior-housing real estate.
- Large-cap pharmaceutical and medical device holdings, including Eli Lilly, AbbVie, Amgen, and Merck, were among the primary contributors to the advance.
- Senior-housing REITs such as Welltower and Ventas also supported the rally as the broader healthcare complex strengthened.
- Over the trailing quarter, the fund gained roughly 6%, extending a longer-term recovery within healthcare.
- For additional perspective, review AGNG's Price Targets and Forecast on dedicated pages.
- Investors seeking automated, data-driven ideas can also explore Trending AI Robots.
Global X Aging Population ETF (AGNG) Overview and Portfolio Exposure
The Global X Aging Population ETF seeks investment results that correspond generally to the price and yield performance of the Indxx Aging Population Thematic Index. The fund is a passively managed, rules-based vehicle that invests in developed-market companies positioned to benefit from longer life spans and the aging of the global population, spanning biotechnology, pharmaceuticals, medical devices, senior living, and specialized healthcare services.
AGNG holds roughly 84 positions and carries a net expense ratio of 0.50%. Its portfolio is heavily concentrated in healthcare at approximately 91% of assets, with real estate making up the remainder through senior-housing and healthcare REITs (real estate investment trusts). Geographically, the fund is diversified but leans toward the United States, which represents about 62% of assets, alongside meaningful exposure to Switzerland, Denmark, Japan, and the United Kingdom.
Among its largest holdings are LLY (Eli Lilly), ABBV (AbbVie), AMGN (Amgen), MRK (Merck), JNJ (Johnson & Johnson), and WELL (Welltower), as well as non-U.S. names including Novo Nordisk and Roche. This top-heavy exposure to large-cap pharmaceuticals and healthcare real estate helps explain why a broad rally in those segments can move the entire fund.
Global X Aging Population ETF (AGNG) Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, AGNG advanced approximately 11%, rising from a level near $36.20 to a closing price of $40.28. The move was not uniform: the fund spent the first part of the period drifting lower to an October trough in the mid-$35 range before staging a sharp, trend-driven recovery that carried it above $41 intraday in early November before settling near $40.
The broader three-month picture is more measured. Over the trailing quarter, the fund gained roughly 6%, moving from about $37.92 to $40.28. This suggests that while the recent one-month advance was pronounced, a portion of it represented a rebound from a mid-cycle pullback rather than an entirely new, uninterrupted uptrend. The pattern indicates a range-bound, then accelerating move rather than a slow, gradual grind higher.
What Drove AGNG Price in the Last 30 Days
The recent advance was primarily a function of the fund's concentrated healthcare exposure. Large-cap pharmaceutical and biotechnology names that dominate the portfolio rallied broadly, lifting the fund's net asset value. Holdings such as Eli Lilly and Amgen, which have delivered strong gains over the past year, remained among the fund's most influential contributors, while diversified healthcare names including AbbVie, Merck, and Johnson & Johnson provided additional support.
The fund's roughly 9% allocation to senior-housing and healthcare REITs also contributed. Welltower and Ventas, which operate senior living and medical office properties, benefited from improving demand trends tied to demographic tailwinds and a more favorable interest-rate environment, since REITs are generally sensitive to borrowing costs and yield expectations.
On a macro level, the rally coincided with renewed investor interest in defensive, cash-generative healthcare businesses. Within a thematic fund as concentrated as AGNG, where a handful of mega-cap pharmaceutical holdings each carry weightings near 3% to 4%, strength in even a small number of positions can generate meaningful index-level performance.
What Drove AGNG Performance Over the Last Quarter
The three-month trend reflects a broader rotation back into healthcare after a period of relative underperformance. Large-cap pharmaceuticals, medical devices, and healthcare services have re-emerged as favored allocations for investors seeking earnings stability and pricing power in an environment marked by shifting interest-rate expectations and moderating inflation pressures.
Institutional flows into thematic and defensive healthcare strategies also supported the fund over the quarter, while the structural theme of global aging continued to underpin demand across its senior-living and chronic-disease franchises. The portfolio's international holdings, including European pharmaceutical companies, added diversification but remained secondary drivers relative to the fund's U.S. large-cap core.
AI Screener
Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps investors scan thousands of securities using technical indicators, fundamentals, volatility metrics, price patterns, industry filters, AI-generated signals, and performance characteristics. The screener is designed to surface trending securities, breakout candidates, and new opportunities more efficiently than manual screening, allowing users to filter by sector, market cap, momentum, and other criteria relevant to their strategy. For investors tracking thematic healthcare funds like AGNG, the platform offers a systematic way to identify comparable opportunities and monitor shifting market leadership.
AGNG ETF Outlook: What Investors Should Watch Next
Going forward, the fund's trajectory will likely hinge on the same forces that drove its recent move. Earnings trends among its largest pharmaceutical holdings, including new-drug pipelines and commercial performance in metabolic and oncology franchises, remain central. Interest-rate expectations are equally important, given the fund's meaningful allocation to rate-sensitive healthcare REITs.
Investors should also monitor inflation data, healthcare policy and drug-pricing regulation, and the pace of institutional flows into thematic and defensive equity strategies. The structural theme of global demographic aging provides a long-term tailwind, but the fund's narrow sector concentration means it can be vulnerable to sector-specific setbacks even when broad equity markets are rising. As always, diversification, valuation, and liquidity considerations will shape how the fund performs relative to both the broader market and its healthcare peers.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AGNG in upward trend: 10-day moving average moved above 50-day moving average on October 23, 2026
The 10-day moving average for AGNG crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on AGNG as a result. In 70 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for AGNG just turned positive on October 13, 2026. Looking at past instances where AGNG's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
AGNG moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where AGNG advanced for three days, in 272 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 246 of 284 cases where AGNG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Bearish Trend Analysis
The 10-day RSI Indicator for AGNG moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 34 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 19 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AGNG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
AGNG broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement